Company newsCompany release
Johnson & Johnson presents new patient experience data on nipocalimab in Sjögren's disease
Among 49 DAHLIAS participants interviewed, mouth dryness was the symptom most often reported and, among those asked, most often prioritized for improvement, the company said.
GetSignal
Johnson & Johnson said on November 7, 2026 that it has new patient experience findings from the Phase 2 DAHLIAS study of nipocalimab in Sjögren's disease. The company said the results show mouth dryness is the symptom improvement that matters most to patients. The findings complement previously reported Phase 2 results, in which an at least 50% increase in saliva production from baseline was seen at Week 24 in 33% of patients on the high-dose 15 mg/kg nipocalimab group, versus 16% on placebo.
Johnson & Johnson said 96% of patients surveyed cited mouth dryness, the most frequently reported symptom. Other core symptoms reported were fatigue (92%), eye dryness (90%), joint pain (73%) and, among women, vaginal dryness (49%). The company said patients who took part in the interviews reported improvements across many of these symptoms during the treatment phase.
The company said the findings helped inform the design of the ongoing Phase 3 study of nipocalimab in Sjögren's disease. The data are among 23 abstracts on nipocalimab to be presented at the American College of Rheumatology Convergence 2026. Johnson & Johnson initiated the Phase 3 DAFFODIL study in adults with moderate-to-severe disease after the Phase 2 results.
Key facts
- Interviewed patients citing mouth dryness
- 96% of 49 participants interviewed
- Interviewed patients citing fatigue
- 92% of 49 participants interviewed
- Phase 2 study
- DAHLIAS, 163 participants
- Conference
- American College of Rheumatology Convergence 2026
Source: The company's release on PR Newswire, November 7, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
Johnson & Johnson first, then the newest- Johnson & Johnson agrees to acquire Ollin Biosciences
JNJ · Johnson & Johnson · Company release · Nov 16, 2026
- Johnson & Johnson says CAPLYTA improved manic symptoms in second Phase 3 study
JNJ · Johnson & Johnson · Company release · Nov 10, 2026
- Johnson & Johnson presents early Phase 1 data on prostate cancer combination
JNJ · Johnson & Johnson · Company release · Nov 8, 2026
